The cohort averaged age 69.6 and 65.9% were men. About 20% were symptomatic, 43% had diabetes, 10.5% had had a previous carotid endarterectomy, and 35.9% a prior coronary stenting or angioplasty.

Embolic Neuroprotection System Reduces Risk Of Cardiac Events, Study Reveals Date: October 22, 2008 Source: Cardiovascular Research Foundation Summary: ...

The main cause of ischemic strokes, which account for 87 percent of all strokes, is atherosclerosis. These fatty deposits, known as plaque, line blood vessel walls and cause blockages. Atherosclerosis ...

Reduce risk of stroke and systemic embolism in non-valvular AF 5mg twice daily; 2.5mg twice daily if patient has any 2 of the following: age ≥80yrs, ≤60kg, or creatinine ≥1.5mg/dL.

EmStop has completed the ‘Controlled Arterial Protection to Ultimately Remove Embolic Material’ (CAPTURE-1) early feasibility clinical study which assessed the EmStop embolic protection system ...

MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the company has received ...

Medical device company marks trial milestone in the evaluation of its embolic protection device, creates expert advisory board as it navigates growth opportunity TAVR, a transcatheter procedure ...

JOPLIN, Mo. — Nearly 800,000 people have a stroke each year, causing tens of thousands of deaths and even more long-term health issues in those who survive. “It’s one of the few things that ...

The FDA has granted premarket approval to the Neuroguard IEP System, a novel stenting system intended to ease the process for individuals with stroke, according to the manufacturer.Contego Medical ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a ...